From an article last week:
Another up-and-comer worth a look is SangStat Medical (SANG), which, along with Abbott Laboratories (ABT), recently won approval from the FDA to market Gengraf, a lower priced version of cyclosporine, which is used to prevent organ transplant rejection.
Gengraf will compete with Neoral, the leading version of cyclosporine, which is marketed by Novartis. The two are interchangeable, according to SangStat and Abbott. Cyclosporine is the leading drug used to prevent graft rejection in transplants. Sales of cyclosporine in the United States run about $480 million annually. In May 15 trading, shares of SangStat -- a money-loser, like Geron --
fell $1.91 to $29.94, down from $48 earlier this year.
I suggest you take your time choosing the right biotech exposure for your investment needs. The bears might not be done with these biotech prices.
Chris |
